Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
levetiracetam, Quantity: 250 mg
Strides Pharma Science Pty Ltd
Levetiracetam
Tablet, film coated
Excipient Ingredients: purified talc; magnesium stearate; povidone; colloidal anhydrous silica; maize starch; titanium dioxide; hypromellose; indigo carmine; macrogol 4000
Oral
60, 30
(S4) Prescription Only Medicine
It is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).
Visual Identification: Blue, oval shaped, biconvex film-coated tablets debossed with a deep break line separating 'E' and '10' on one side and plain on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2011-12-23